136 related articles for article (PubMed ID: 16628279)
1. [Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly].
Casini AF; Araújo PB; Fontes R; Xavier SS; Gadelha MR
Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):82-90. PubMed ID: 16628279
[TBL] [Abstract][Full Text] [Related]
2. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.
Lim MJ; Barkan AL; Buda AJ
Ann Intern Med; 1992 Nov; 117(9):719-26. PubMed ID: 1416573
[TBL] [Abstract][Full Text] [Related]
3. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
[TBL] [Abstract][Full Text] [Related]
4. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.
Colao A; Marzullo P; Cuocolo A; Spinelli L; Pivonello R; Bonaduce D; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 2003 Feb; 58(2):169-76. PubMed ID: 12580932
[TBL] [Abstract][Full Text] [Related]
5. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass.
Vitale G; Galderisi M; Pivonello R; Spinelli L; Ciccarelli A; de Divitiis O; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2004 Mar; 60(3):343-9. PubMed ID: 15009000
[TBL] [Abstract][Full Text] [Related]
7. [CLINICAL, BIOCHEMICAL AND HORMONAL PREDICTORS OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ACROMEGALY].
Mykytyuk MR
Lik Sprava; 2015; (5-6):34-40. PubMed ID: 27089713
[TBL] [Abstract][Full Text] [Related]
8. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
10. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.
De Marinis L; Bianchi A; Mazziotti G; Mettimano M; Milardi D; Fusco A; Cimino V; Maira G; Pontecorvi A; Giustina A
Pituitary; 2008; 11(1):13-20. PubMed ID: 17987389
[TBL] [Abstract][Full Text] [Related]
11. Acromegalic cardiomyopathy. Left ventricular filling and hypertrophy in active and surgically treated disease.
Rossi E; Zuppi P; Pennestrí F; Biasucci LM; Lombardo A; De Marinis L; Loperfido F
Chest; 1992 Oct; 102(4):1204-8. PubMed ID: 1395769
[TBL] [Abstract][Full Text] [Related]
12. Effects of growth hormone and insulin-like growth factor-1 on cardiac hypertrophy of hypertensive patients.
Sesti G; Sciacqua A; Scozzafava A; Vatrano M; Angotti E; Ruberto C; Santillo E; Parlato G; Perticone F
J Hypertens; 2007 Feb; 25(2):471-7. PubMed ID: 17211256
[TBL] [Abstract][Full Text] [Related]
13. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.
Lombardi G; Colao A; Marzullo P; Biondi B; Palmieri E; Fazio S;
J Endocrinol Invest; 2002 Dec; 25(11):971-6. PubMed ID: 12553557
[TBL] [Abstract][Full Text] [Related]
14. Cardiac effect of thyrotoxicosis in acromegaly.
Marzullo P; Cuocolo A; Ferone D; Pivonello R; Salvatore M; Lombardi G; Colao A
J Clin Endocrinol Metab; 2000 Apr; 85(4):1426-32. PubMed ID: 10770177
[TBL] [Abstract][Full Text] [Related]
15. Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly.
Fukuoka H; Takahashi Y; Iida K; Kudo T; Nishizawa H; Imanaka M; Takeno R; Iguchi G; Takahashi K; Okimura Y; Kaji H; Chihara K
Horm Res; 2008; 69(3):165-71. PubMed ID: 18219220
[TBL] [Abstract][Full Text] [Related]
16. Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance.
Bogazzi F; Lombardi M; Strata E; Aquaro G; Lombardi M; Urbani C; Di Bello V; Cosci C; Sardella C; Talini E; Martino E
J Endocrinol Invest; 2010 Feb; 33(2):103-8. PubMed ID: 20348836
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone, acromegaly, and heart failure: an intricate triangulation.
Saccà L; Napoli R; Cittadini A
Clin Endocrinol (Oxf); 2003 Dec; 59(6):660-71. PubMed ID: 14974906
[TBL] [Abstract][Full Text] [Related]
18. Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort.
dos Santos Silva CM; Gottlieb I; Volschan I; Kasuki L; Warszawski L; Balarini Lima GA; Xavier SS; Pedrosa RC; Neto LV; Gadelha MR
J Clin Endocrinol Metab; 2015 Dec; 100(12):4447-55. PubMed ID: 26431508
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
[TBL] [Abstract][Full Text] [Related]
20. Diabetes mellitus in a cohort of patients with acromegaly.
Rodrigues TC; Costenaro F; Fedrizzi D; Oliveira MD; Lima PB; Boschi V; Czepielewski MA
Arq Bras Endocrinol Metabol; 2011 Dec; 55(9):714-9. PubMed ID: 22231975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
